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Abstract
Objectives: The forced swim test (FST) is a commonly used model to predict antidepressant efficacy. Uncovering the
genetic basis of the model may unravel the mechanism of antidepressant treatment.
Methods: FVB/NJ (FVB) and C57BL/6J (B6) were first identified as the response and non-response strains to fluoxetine (a
serotonin-specific reuptake inhibitor antidepressant) treatment in the mouse FST. Simple-interval (SIM) and composite-
interval (CIM) mappings were applied to map the quantitative trait loci (QTLs) of the anti-immobility effect of fluoxetine in
FST (FSTFLX) in 865 male B66FVB-F2 mice. The brain mRNA expressions of the gene with the maximum QTL-linkage signal
for FSTFLX after the FST were compared between B6 and FVB mice and also compared between fluoxetine and saline
treatment. The association of the variants in the human homologue of the mouse FSTFLX-QTL gene with major depressive
disorder (MDD) and antidepressant response were investigated in 1080 human subjects (MDD/control=582/498).
Results: One linkage signal for FSTFLX-QTL was detected at an intronic SNP (rs6215396) of the mouse Zfp326 gene (maximal
CIM-LOD=9.36). The Zfp326 mRNA expression in the FVB thalamus was significantly down-regulated by fluoxetine in the
FST, and the higher FVB-to-B6 Zfp326 mRNA expressions in the frontal cortex, striatum and hypothalamus diminished after
fluoxetine treatment. Two coding-synonymous SNPs (rs2816881 and rs10922744) in the human homologue of Zfp326,
ZNF326, were significantly associated with the 8-week antidepressant treatment response in the MDD patients (Bonferroni-
corrected p=0.004–0.028).
Conclusions: The findings suggest the involvement of the Zfp326 and ZNF326 genes in antidepressant treatment response.
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Introduction
Antidepressants are the main biological treatment for major
depressive disorder (MDD). However, there are inter-individual
differences in the response to antidepressant treatments: regardless
of the kind of antidepressant used for initial treatment, 30–50% of
patients do not respond sufficiently [1–5]. Although the mecha-
nism and factors affecting individual responsiveness to antidepres-
sants are yet unknown, several observations have demonstrated
a high concordance of responsiveness to antidepressants in first-
degree relatives [6–8], indicating that antidepressant efficacy is at
least partly under genetic control [9].
The brain structure, neuronal signaling, circuits and genomic
sequence between humans and mouse are highly conserved. With
few exceptions, each human gene has a mouse ortholog and vice
versa [10,11]. Therefore, exploring the genetic mechanisms of
mouse behavior may shed light on fundamental elements of
human behavioral regulation [12], including responses to anti-
depressants.
It is thought that drug response is a complex and polygenic trait.
To dissect the genetic bases of the trait, many studies have used
quantitative trait locus (QTL) analysis to identify genomic loci
associated with responsiveness to specific drugs [13]. The analysis
is a statistical method that links phenotypic data and genotypic
data. The QTL approach has successfully pinned down the Usp46
gene that regulates the mouse baseline immobility time in the tail
suspension test (TST) and forced swim test (FST) [14]. A similar
approach also found the involvement of Rgs2 gene in mouse
anxiety [15]. The TST and FST are the most commonly used
methods in animals to predict the efficacy of antidepressants.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e32984Crowley et al. identified two coding non-synonymous single
nucleotide polymorphisms (Leu117Pro and Ser505Pro) in the
mouse vesicular monoamine transporter 2 gene that could be the QTL
for the TST response to cilatopram treatment [16]. Liu et al.
analyzed the NMRI6129S6 F2 mouse TST response to the
tricyclic antidepressant imipramine and identified three suggestive
chromosome regions (chromosome 1, 4 and 5) that might contain
QTLs affecting the behavioral response [17]. Although several
QTLs for the TST response to antidepressants have been
identified, it is unclear whether the mouse FST response to
antidepressants shares these QTLs. Most importantly, it remains
unclear whether QTLs for the mouse response to antidepressants
could be applied to predict human responses to antidepressants. In
this study, we applied QTL analysis to localize the loci affecting
the FST response to fluoxetine treatment in mice and used human
samples to validate our findings.
Materials and Methods
Ethics
The study comprised an animal part and a human part. The
animal part of the study was carried out in strict accordance with
the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Laboratory Animal Center,
and was conducted with the approval of the Institutional Animal
Care and Use Committee of Taipei Veterans General Hospital
(approved on 2007/10/15) and National Taiwan Ocean Univer-
sity (approval ID: 96009). The animals were sacrificed by carbon
dioxide narcosis, and all efforts were made to minimize suffering.
The human part of the study was approved by the Institutional
Review Board of Taipei Veterans General Hospital (VGHIRB
No.: 95-11-07) and E-DA hospital (E-MRP-095-014), and written
informed consent was obtained from the participants prior to
enrollment.
Animal and Drug Treatment
Animals were housed in plastic cages (five mice per cage) in
a room maintained at a temperature of 2461uC under a standard
12-hour light/dark cycle (lights on from 9:00 a.m. to 9:00 p.m.).
Food and water were provided ad libitum. C57BL/6J (B6),
BALB/cByJ (BALB) and FVB/NJ (FVB) were obtained from the
National Laboratory Animal Center, Taiwan (http://www.nlac.
org.tw/english/default.asp), and DBA/2N (DBA) and C3H/HeN
(C3H) were purchased from BioLASCO Taiwan Co., Ltd (http://
www.biolasco.com.tw/). F1 mice were generated by intercrossing
the antidepressant-sensitive and antidepressant-insensitive strains,
and F2 mice were obtained by intra-crossing the F1 mice. To
avoid the potential influence of fluctuating estrogen and pro-
gesterone in the estrus cycle on the FST, only male mice were used
throughout the study.
Fluoxetine hydrochloride (SIGMA) was prepared freshly and
dissolved in deionized water in a volume of 4 ml/kg. Saline or
fluoxetine was administered to the mice through intra-peritoneal
injection (ip) 30 minutes prior to the FST. In studying strain
differences in response to fluoxetine treatment, each animal of the
same strain was randomly assigned to the following treatment
groups: saline (4 ml/kg), 5 mg/kg, 10 mg/kg, or 20 mg/kg of
fluoxetine. In the experiments for heritability and quantitative trait
locus (QTL) analysis, all the F1 and F2 mice received 20 mg/kg of
fluoxetine.
Behavior Measurement: the FST
Each animal was tested in the FST at 8–10 weeks of age. The
FST was conducted between 10:00 and 16:00 on two consecutive
days. On day 1, animals were placed in an acrylic plastic box filled
with water (23–24uC, 15 cm in depth) for 6 minutes. The total
immobility time in the last 4 minutes (FSTBAS) was recorded
[18,19]. Twenty hours later, saline or fluoxetine was administered
to the mouse 30 minutes prior to the same procedure as that of day
1, and the total immobility time (FSTFLX) was recorded. We used
a digitalized apparatus, Method and System for Measuring
Mobility of a Tested Animal (USA Invention Patent No.: US
7,121,229), to standardize the measurements of the FST.
Agreement between the instrumental measurements and tradi-
tional naked-eye measurements for immobility time was high
(Pearson correlation =0.932–0.957, p,0.001).
Behavior Measurement: the Open Field Test
30 minutes after saline or fluoxetine (20 mg/kg) treatment mice
were individually placed in an enclosed obstacle-free space
(90690630 cm, L6W6H). The ambulatory distance (cm), time
spent in traveling and traveling speed of the studied mice were
measured by a video tracking system (Diagnostic & Research
Instruments Co., Taiwan) for 6 minutes, corresponding to the
observation period in the FST.
Human Subjects and Assessments of Responses to
Antidepressant Treatments
This study enrolled 582 patients with MDD and 498 controls.
An author (YWY) who was blind to each subject’s genotype used
the Schedules for Clinical Assessment in Neuropsychiatry (SCAN)
[20] to assess the patients and made the diagnosis of MDD
according to the DSM-IV. Patients who had additional Axis-I
diagnoses (including schizophrenia, bipolar disorder, substance use
disorder, anxiety disorder, etc.), pregnant patients, those who
recently attempted suicide, and those with any major medical
and/or neurological disorders were excluded. The control subjects
screened by board-certificated psychiatrists were all free from
major psychiatric illness. All the participants were aged between
20 and 65 years. Parts of the cases have been studied in our
previous work [21–24].
In the MDD group, 262 patients were further evaluated in
terms of their response to 8 weeks of treatment with fluoxetine or
citalopram, both of which are selective serotonin reuptake
inhibitors (SSRIs), to reduce pharmacological variability in terms
of pharmacogenetic study of the antidepressants [25]. These
patients had a minimum total score of 18 in the 21-item Hamilton
Depression Rating Scale (HAMD) prior to treatment. The dose of
both drugs started from 20 mg/day, which could be increased to
40 mg/day on the basis of clinical presentation and judgment.
During the evaluation period, the use of any other psychotropic
drugs was forbidden, except for night-time benzodiazepines for
insomnia. For those patients with a past treatment history, a two-
week drug-free interval was required before entering the study.
Responders were defined as having a greater than 50% decrease in
total HAMD score after 8 weeks of treatment. All the participants
were Han Chinese.
Marker Selection & Genotyping
For mapping of the mouse FSTFLX, we used the ENU Mouse
Gene Mapping Panel (http://nrpgm.sinica.edu.tw/en/
serviceDetail.php?cNo=75), which consists of two single nucleo-
tide polymorphisms (SNPs) on chromosome X and 197 SNPs on
autosomal chromosomes to distinguish B6 from the FVB genetic
background. In the analysis of human antidepressant response,
two coding synonymous SNPs, rs2816881 C.A (Val412Val) and
rs10922744 A.G (Glu505Glu), in the human ZNF326 gene were
Zinc Finger Protein 326 and Antidepressant
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information listed in the International HapMap Project (http://
hapmap.ncbi.nlm.nih.gov/index.html.en). The ZNF326 gene is
the human homologue of the mouse Zfp326 gene. The two SNPs
tag 100% of the genetic variations in ZNF326 in the CHB
population, under the marker selection criteria of no less than 10%
of the minor allele frequency, greater than 0.8 in r
2 and two- and
three-marker aggressive tagging with Haploview V4.1 (http://
www.broadinstitute.org/haploview/haploview-downloads).
High-throughput MALDI-TOF mass spectrometry was
adopted to genotype the SNPs. In genotyping the mouse samples,
one B6, FVB and two F1 genomic DNAs were included as internal
controls. For the human samples, 24 randomly selected subjects
were re-genotyped for rs2816881 and rs10922744. The genotyp-
ing consistency rates for rs2816881 and rs10922744 were 100%
and 96%, respectively.
Quantification of mRNA Expression in the Mouse Brain
To quantify the Zfp326 mRNA expression in different brain
regions of the mouse, a new batch of B6 (n=20) and FVB (n=20)
mice were subjected to the two-day FST and were also treated
with saline or 20 mg/kg of fluoxetine 30 minutes before the 2
nd
FST on the second day. At the end of the 2
nd FST, the animals
were sacrificed immediately, and the frontal cortex, striatum,
nucleus accumbens, thalamus, hypothalamus, amygdala and
hippocampus were dissected and stored in RNAlater (Ambion).
Total RNA of individual brain regions was extracted with TRIzol
(Invitrogen), treated with DNase I (Promega) and then transcribed
to complimentary DNA (cDNA) using Moloney Murine Leukemia
Virus (MMLV) reverse transcriptase according to the manufac-
turer’s instructions. RNA was quantified using absorption of light
at 260 and 280 nm. The amounts of Zfp326 and cyclophilin A
cDNAs were measured using SYBR green-based real-time
quantitative polymorphism chain reaction (RT-qPCR), which
was performed using a Rotor-Gene 3000H (Corbett, Sydney,
Australia), and the relative cDNA levels of Zfp326 were
normalized by the amount of cyclophilin A cDNA in the same
sample. Cyclophilin A is an immediate factor of calcium/calmodulin
signaling that is expressed ubiquitously [26]. The gene is expressed
at a ‘‘high’’ level (.100 copies per cell) and its expression is less
variable and more stable than that of GAPDH and beta-actin in
the rat ischemia hippocampus and striatum [27], in experimental
brain trauma in mice [28], and in a mouse model of kainite-
induced mesiotemporal epilepsy [29]. It is also one of the most
reliably expressed endogenous reference genes in the brain of
those with Alzheimer’s disease [30]. Therefore, cyclophilin A
appears to be a suitable internal or reference control in the
quantitation of CNS mRNA expression [31,32], was selected as an
endogenous reference cDNA normalizer in this study.
A specific sample cDNA was used as a relative standard and
inter-assay controller in each batch of RT-qPCR throughout the
measurements of Zfp326 and cyclophilin A cDNA. The primer
sequences for Zfp326 were zfp326-F: 59-TGCAGATGATCA-
CATGAT-39 and zfp326-B: 59-CCTGAGGGTGATCTTGAA-
39; for cyclophilin A, cyclophilin-A-F1:59-TATAAAG-
GAAGCCGCGGCGA-39 and cyclophilin-A-B1:59-
CTTTGTCTGCAAACAGCTCGA-39. To obtain a reliable
quantitative measurement of mouse brain cDNA, a linear
standard curve was generated for each experiment plate. The
standard curve was generated with serial 4-fold dilution to four
dilution levels from one reference brain cDNA (R
2.0.9). In all the
experiments, the lowest and highest detection limits from the
standard curves for Zfp326 and cyclophilin A expression were as
follows: Zfp326: lower =18.8,19.3 Ct/upper =25.4,25.8 Ct;
cyclophilin A: lower =18.0,18.6 Ct/upper =25.3,25.6 Ct (Ct:
the PCR cycle at which the sample reached the threshold). A
sample with a Ct value residing in the linear range between the
two detection limits was regarded as a reliable measurement. All
samples were run in duplicate on the sample experiment plate.
The intra-assay and inter-assay CVs for Zfp326 and cyclophilin A
mRNA were 0.8% and 2%, respectively. Data were derived from
the mean of two independent amplifications.
Statistical Analysis
The details of the analysis for the quantitative and qualitative
traits measured in the study are summarized in the supplementary
materials. In the QTL analysis for FSTFLX, we first used simple
interval mapping (SIM) in R/qtl (http://www.rqtl.org/) [33] to
scan the potential region harboring the QTL for FSTFLX.A
‘‘normal model’’ was used to scan the whole genome for normally-
distributed phenotypes. However, for the phenotypes that deviated
from a normal distribution, we performed the ‘‘non-parametric
form of interval mapping’’ [33]. To control the residual genetic
effect on SIM-detected signals, composite interval mapping (CIM)
in R/qtl, a combination of SIM and multiple linear regression, was
applied [34,35]. The empirical genome-wide significant thresholds
of 3.33 for SIM and 4.68 for CIM were obtained from 1000
permutation tests. The lowest LOD for suggestive linkage was set
at 2.8 according to the guidelines proposed by Lander et al. [36].
In the C576FVB F2 population, FSTFLX was positively
correlated with FSTBAS (Pearson correlation coefficient =0.35,
p,0.001). To reduce the confounding effect of FSTBAS on
FSTFLX, the standardized residual of FSTFLX (i.e., z_ FSTFLX)
was obtained with linear regression by treating FSTBAS as
a covariate [17,37]. The z_ FSTFLX was then subjected to QTL
scanning with SIM and CIM. The empirical genome-wide
significant thresholds of SIM and CIM for the phenotype were
3.38 and 4.08, respectively. The lowest LOD for suggestive linkage
was also set at 2.8 [36].
In humans, the linkage between ZNF326 rs2816881 and
rs10922744 was estimated with Haploview V4.1. The difference
in the haplotype frequency between groups was compared using
SNPAlyze V3.5 (http://www.dynacom.co.jp/english/). The sig-
nificance of the comparison was determined after 100000
permutation tests. As we tested two phenotypes (major depression
diagnosis and treatment response after 8 weeks of antidepressant
treatment) and two SNPs, the correction factor was 4, and a p-
value lower than 0.0125 was regarded as significant.
Results
FSTBAS in Different Mouse Strains
There were significant differences in the FSTBAS among strains
(F(4,227)=27.84, p,0.001) (Table S1). Post hoc Scheffe ´’s pro-
cedure showed the following differences (p,0.05): BALB.B6,
FVB, DBA, C3H; B6.C3H; FVB/NJ.C3H and DBA/
2N.C3H. The FSTBAS of B6 and FVB were similar.
Surveying FSTFLX in Different Mouse Strains
The mean FSTFLX in the B6 mice was not affected by
administration of fluoxetine (F(3,38)=0.76, p=0.522, Figure 1a).
However, a significant difference in the mean FSTFLX was
observed in the BALB mice treated with various doses of
fluoxetine (Figure 1b, F(3,44)=4.198, p=0.011). Post hoc Dun-
nett’s analysis indicated that the 20 mg/kg group had a lower
FSTFLX than the saline group (p=0.011). The FVB mice showed
dose-dependent responses to fluoxetine in the FST (F(3,50)=5.54,
p=0.002, Figure 1c). The 20 mg/kg group’s FSTFLX was
Zinc Finger Protein 326 and Antidepressant
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p=0.002), while the difference between the 10 mg/kg saline
groups was borderline (p=0.054). The FSTFLX of the DBA and
C3H mice was not changed by the administration of different
doses of fluoxetine (DBA: F(3,39)=0.44, p=0.723, Figure 1d;
C3H: F(3,41)=0.18, p=0.931, Figure 1e). The survey suggested
that the BALB and FVB mice were the fluoxetine-sensitive strains
and B6 was the fluoxetine-insensitive strain in the FST.
Confirmation of the Sensitive and Insensitive Strains in
Response to Fluoxetine Treatment
In order to confirm the sensitive and insensitive strains in
response to fluoxetine treatment, we used further batches of
BALB, FVB and B6 mice and 20 mg/kg of fluoxetine to repeat the
FST. In the FVB mice the fluoxetine group showed a shorter
FSTFLX than the saline group (fluoxetine (n=8) vs. saline (n=8):
142.3623.6 vs. 175.4615.2 sec, two-tailed independent t test,
p=0.005). In the B6 mice, there was no significant difference in
the FSTFLX between the fluoxetine and saline groups (fluoxetine
(n=8) vs. saline (n=8): 210.2614.1 vs. 212.466.0 sec, two-tailed
independent t test, p=0.688). The results of the BALB mice were
inconsistent with those of the survey experiments (fluoxetine (n=9)
vs. saline (n=8): 193.7615.4 vs. 206.1618.5 sec, two-tailed
independent t test, p=0.154). The results confirmed FVB to be
the fluoxetine-sensitive strain and B6 to be the fluoxetine-
insensitive strain in the FST.
Open Field Test
In order to rule out the possibility that fluoxetine may induce
hyperactivity [38,39], open field tests were conducted 30 minutes
after fluoxetine (20 mg/kg) administration in independent batches
of experimentally naı ¨ve B6 and FVB mice. There was no
significant difference in the mean traveling distance, time spent
in traveling and the speed of traveling between the mice treated
with saline and those treated with fluoxetine in both mouse strains
(Table S2, all p.0.1).
Heritability Study
B6 (fluoxetine-insensitive strain) and FVB (fluoxetine-sensitive
strain) mice were crossed to produce the F1 progeny. The F1 mice
were intra-crossbred to generate the F2 progeny. The mean and
variance of the FSTFLX of the B6, F1, F2 and FVB were as listed
in Table S3. The mean FSTFLX were significantly different among
the B6 (n=19), F1 (n=112), F2 (n=865) and FVB (n=22) mice
(Figure 2, FSTFLX: Kruskal-Wallis test, p,0.0001). The post hoc
Mann-Whitney test revealed that the B6 mice had the longest
FSTFLX (214.7613.7 sec, least sensitive), F1 and F2 the in-
termediate FSTFLX (F1:204.4624.5 sec; F2:195.0632.2 sec), and
FVB the shortest FSTFLX (165.1626.6 sec, most sensitive) (B6.
FVB, all p,0.0001, F1$F2.FVB, all p,0.0001). As the F1 mice
are genetically homogeneous, the broad-sense heritability (H
2) for
the F2 FSTFLX was 0.42 [(1039.7–602.4)/1039.7] [40]. The
narrow-sense heritability (h
2) due to all additive genetic contribu-
tions on FSTFLX variation of the F2 (VA/VF2) was 0.30. The
heritability due to dominance (VD/VF2) was 0.06 (Table S3) [40].
QTL Analysis for the FST Response to Fluoxetine
Using SIM, we identified 11 consecutive SNPs with LOD scores
greater than the genome-wide significant threshold of 3.27
(Table 1). All the 11 SNPs are located in mouse chromosome 5,
with a 2-LOD confidence interval (2-LOD CI) spanning the
47.3 cM to 54.2 cM region (Figure 3). Under the additive model,
the 11 SNPs contributed 1.6%,4.7% of the inter-individual
variation in the FSTFLX (Table 1). The F2 mice with homozygous
FVB alleles on these SNPs had a significantly shorter FSTFLX than
the heterozygotes or homozygous B6 alleles (Table 1), suggesting
that the F2 mice’s FST responsiveness to fluoxetine was affected by
the alleles of the FVB mice. The results of the SIM and CIM for
FSTFLX are compared and plotted in Figure 3. Although the LOD
scores of some chromosome 5 markers obtained from the two
algorithms were not always consistent, the maximum linkage
signal detected by the SIM and CIM emerged on the same SNP
rs6215296, with a LOD score of 8.21 in the SIM and 9.36 in the
CIM. The inconsistency in the LOD scores obtained from the two
programs for the other markers may arise from residual genetic
influences on adjacent markers, an effect that is taken into account
in the CIM but not in the SIM [35].
In the F2 mice, about 13% of the individual variation in
FSTFLX was correlated with their FSTBAS (FSTFLX vs. FSTBAS:
Pearson correlation coefficient =0.35, p,0.001). It is possible that
the identified FSTFLX-QTL is partly contributed to by the
FSTBAS. Therefore, the effect of FSTBAS was removed from each
F2 mouse’s FSTFLX through linear regression. The standardized
residuals of each F2 mouse’s FSTFLX (ie, z_ FSTFLX) were then
subjected to the SIM and CIM. One signal of z_ FSTFLX was
linked to mouse chromosome 5 in the SIM and CIM (Figure S1).
Again, both programs’ optimal results converged on rs6215296,
with a LOD of 4.75 in the SIM and 4.80 in the CIM. The results
were consistent with that using FSTFLX (Figure 3 for FSTFLX),
indicating that the SNP is a specific QTL for the mouse FST
response to fluoxetine.
Associations between Mouse Zfp326 Exonic
Polymorphisms and Mouse FST Responses to Fluoxetine
The maximum linkage signal for the FST response to fluoxetine
is located on rs6215296 (Figure 3 and Figure S1), a SNP of the
mouse Zfp326 gene. There are two exonic SNPs in the mouse
Zfp326 that distinguish B6 from FVB mice: rs33550587 is a coding
nonsynonymous SNP (Asp494Gly) in exon 12, while rs13473815 is
a polymorphism in the 3-untranslated region (39-UTR) (http://
www.informatics.jax.org/strains_SNPs.shtml). In silico analysis
predicted that different alleles of rs33550587 transcribe into
different secondary structures of Zfp326 mRNA (Figure S2a), and
the same goes for rs13473815 (Figure S2b). To further study the
effect of Zfp326 variations on mouse responses to fluoxetine, the
B66FVB F2 mice were genotyped for the two Zfp326 SNPs. For
rs33550587, the F2 mice carrying one or two FVB alleles exhibited
a shorter FSTFLX than the F2 carrying homozygous B6 alleles
(F(2,827)=21.9, p=5.5610
210, post hoc Dunnett t test: B6/B6 vs.
B6/FVB, p=.032; B6/B6 vs. FVB/FVB, p=3.8610
29,
Figure 4a). A similar finding was noted with rs1373815
(F(2,826)=21.9, p=5.6610
210, post hoc Dunnett t test: B6/B6
vs. B6/FVB, p=0.033; B6/B6 vs. FVB/FVB, p=3.8610
29,
Figure 4b). The two SNPs rs33550587 and rs13473815 are in
strong linkage disequilibrium (LD, absolute D’=1.0, r
2=1.0) with
rs6215296, suggesting that the maximal detected LOD score of
rs6215296 may reflect the effect of rs33550587 and rs13473815 on
FSTFLX through inter-marker LD.
Zfp326 mRNA Expressions in the Mouse Brain
The mRNA levels of the reference gene cyclophilin A in the
selected brain regions of B6 and FVB were not regulated by the
treatment with fluoxetine in the FST (Table S4), indicating that
cyclophilin A is an appropriate endogenous reference gene for use in
this study. Figure 5 shows the Zfp326 mRNA expression in
different brain regions of B6 or FVB mice after 20 mg/kg of
fluoxetine treatment. Significant inter-strain differences in Zfp326
Zinc Finger Protein 326 and Antidepressant
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e32984mRNA expression between B6 and FVB were noted in the frontal
cortex, hippocampus, hypothalamus, amygdala, nucleus accum-
bens and striatum (Mann-Whitney U test, all p,0.05). However,
after fluoxetine treatment, the inter-strain difference in the frontal
cortex, hypothalamus and striatum disappeared (Figure 5). Fur-
thermore, in FVB, the Zfp326 mRNA levels in the thalamus were
significantly lower in the fluoxetine group than in the saline group
(Mann-Whitney test, p=0.027).
Association between Human ZNF326 Variations and
Responses to SSRI Antidepressant Treatments
There are two coding-synonymous SNPs in the human ZNF326
gene (rs2816881 (Val412Val) and rs10922744 (Glu505Glu)). They
tag 100% of the overall ZNF326 genetic variations in the CHB
population recruited in the international HapMap project (http://
hapmap.ncbi.nlm.nih.gov/). In the study, the gender proportions
and mean age of the MDD and control groups were similar
(gender (male/female): MDD vs. control =238/344 vs. 220/278,
p=0.276; age (SD): MDD vs. control =44.3 (16.4) vs. 43.1 (12.6),
p=0.218). There was no significant difference between the
responders and non-responders in terms of gender distribution,
antidepressants (fluoxetine or citalopram), mean age, duration of
current episode, number of previous episodes and mean baseline
HAMD scores (Table S5, all p.0.05).
Table 2 shows the genotype and allele distributions in the study
subjects. The genotype distributions of the two SNPs in the MDD
and control subjects were in Hardy-Weinberg equilibrium. The
genotype and allele distributions of the two ZNF326 SNPs were
similar between the MDD patients and controls, but were
significantly different between the responders and non-responders.
The A-carrier rate of rs2816881 was higher in the responders
(15.3%) than in the non-responders (3.3%) (Fisher’s exact
p=0.003, odds ratio (OR) for being the responder =5.20, 95%
CI=1.53–17.69). Similarly, the G-carrier rate of rs10922744 was
higher in the responders (15.7%) than in the non-responders
(3.4%) (Fisher’s exact p=0.002, OR for being the responder
=5.34, 95% CI=1.57–18.12). Haplotype-based analysis for
rs2816881–rs10922744 did not further increase the significance
(data not shown) because they are highly linked (absolute D’=1.0,
r
2=1.0). The association between the two ZNF326 SNPs and
antidepressant treatment response survived the corrections for
multiple comparisons.
Discussion
Identification of the QTL for Mouse Sensitivity to
Fluoxetine
FST and TST are usually served as convenient animal models
for predicting the efficacy of antidepressants. Several mouse
chromosome regions (chromosomes 1, 4, 5, 7, 12 and 19) have
been linked to the mouse response to antidepressants in the TST
using QTL mapping [16,17]. However, the genetic determinants
underlying the response to antidepressant in the mouse FST have
not been extensively studied. In this study, we applied QTL
mapping to narrow down the genetic factors affecting the mouse
FST response to fluoxetine in 865 male B66FVB F2 mice. Both
the SIM and the CIM algorithms consistently revealed linkage
signals in the 26.8–60.3 cM region of chromosome 5 (2-LOD CI
=47.3–54.2 cM) (Table 1 & Figure 3). The results suggest that the
region contains the QTL of the mouse FST response to fluoxetine.
Interestingly, Liu et al. reported that D5Mit41 (0.25 cM away
from rs6215296) was a suggestive QTL (LOD =2.9) for mouse
sensitivity to imipramine treatment in the TST [17]. The close
proximity of rs6215296 and D5Mit41 indicates that the 47.3–
54.2 cM region of chromosome 5 contains shared QTL(s)
modifying responses to antidepressants in the TST and FST.
There are five other suggestive QTLs thought to be associated
with the anti-immobility effect of antidepressant in the TST.
Crowley et al. reported that one significant QTL on mouse
chromosome 19 (D19Mit71) and two suggestive QTLs on
chromosome 7 (D07Mit259) and chromosome 12 (D12Mit118)
were associated with mouse responses to citalopram, another SSRI
antidepressant, in the TST [16]. The other suggestive QTLs
(D1Mit410 and D4Mit204) for response to imipramine in the TST
were reported in the work of Liu et al. [17]. However, we did not
obtain significant LOD scores in those regions in this study. The
inconsistencies among studies might arise owing to the different
parental strains (ex, Balb/cJ6A/J vs. NMRI6129S6 vs.
B66FVB), behavioral paradigms (TST vs. FST), sample sizes
and/or the use of antidepressants (e.g., imipramine, citalopram or
fluoxetine).
Strain Difference and Fluoxetine Treatment on Zfp326
Expression in the Brain
The maximum linkage signal for the FST response to fluoxetine
is located on rs6215296. Since the SNP is located on mouse Zfp326
gene, we looked into Zfp326. Except for limited evidence of
involvement in neuronal differentiation [41], the function of
Zfp326 has rarely been explored. We investigated the expression
profiles of Zfp326 in the brain of FVB and B6 mice. The Zfp326
Figure 1. Strain-specific response to fluoxetine in mouse FST. Immobility time in the FST of B6 (1a), BALB (1b), FVB (1c), DBA (1d) and C3H
(1e) mice after administration of different doses of fluoxetine. The FST was conducted 30 minutes after fluoxetine or saline injection (i.p.). ‘‘*’’ denotes
a p-value lower than 0.05 compared with the saline group in the post hoc analysis. FST: forced swim test.
doi:10.1371/journal.pone.0032984.g001
Figure 2. FST response to fluoxetine in B6, F1, F2 and FVB
mice. Immobility time in the FST for B6 (n=19), FVB (n=22) and their
F1 (n=112) and F2 (n=838) mice after fluoxetine treatment. The FST
was conducted 30 minutes after fluoxetine (20 mg/kg) or saline
injection (i.p.).‘‘*’’ denotes a p-value lower than 0.05 in post hoc
analysis compared with the FVB mice. FST: forced swim test; i.p.:
intraperitoneal.
doi:10.1371/journal.pone.0032984.g002
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of the B6 mice in the frontal cortex, hypothalamus and striatum,
but the inter-strain difference became insignificant after fluoxetine
treatment (Figure 5). Furthermore, in the thalamus of FVB, the
Zfp326 mRNA expression was down-regulated by fluoxetine
treatment (Figure 5). Interestingly, the four regions are thought
to be involved in the cognitive aspect (feelings of worthlessness and
guilt), neuro-vegetative signs and hedonic deficit of depression
[42]. The results that Zfp326 mRNA levels are different in some
brain areas of B6 and FVB mice and that Zfp326 mRNA can be
regulated by fluoxetine in some brain areas may suggest a role of
Zfp326 in regulating mouse sensitivity to fluoxetine and partly
Table 1. Mouse single nucleotide polymorphisms (SNPs) that were associated with immobility time in the FST after fluoxetine
treatment (FSTFLX).
























rs13459086 26.8 3.28 0.00 1.6 200.5 (30.0, 227) 195.1 (33.6, 415) 188.7 (32.8, 193) 0.001 FVB Gpr125
rs13478271 31.7 4.01 0.21 1.8 200.2 (30.0, 220) 196.0 (33.0, 420) 187.4 (33.5, 196) ,0.001 FVB Pcdh7,
LOC100041385
rs6167151 32.8 4.67 0.04 2.2 201.4 (29.3, 218) 195.3 (33.4, 423) 187.2 (33.2, 193) ,0.001 FVB Tbc1d1, Ppia-
ps22,
LOC433894
rs6366606 38.9 5.39 0.01 2.8 202.7 (28.6, 219) 195.0 (32.9, 423) 186.9 (34.5, 193) ,0.001 FVB Dcun1d4
rs13478385 44.3 6.55 0.08 3.6 203.2 (28.2, 212) 195.8 (32.1, 413) 185.5 (35.6, 207) ,0.001 FVB Adamts3
rs6232866 46.0 6.12 0.14 3.4 203.0 (28.2, 214) 195.8 (32.2, 415) 185.6 (35.7, 205) ,0.001 FVB G3pb2, Vdp
rs13478403 47.3 6.91 0.04 3.0 203.2 (27.6, 205) 197.4 (29.8, 391) 188.0 (36.6, 191) ,0.001 FVB Fras1
rs13478418 48.5 7.35 0.32 4.1 203.1 (28.4, 217) 196.1 (31.1, 410) 184.3 (36.8, 208) ,0.001 FVB LOC666417
rs6215296 50.9 8.21 9.36 4.7 202.9 (28.2, 235) 197.4 (30.8, 389) 183.2 (36.6, 207) ,0.001 FVB Zfp326
rs13478462 54.2 7.49 0.43 4.6 203.1 (27.5, 238) 196.2 (31.6, 391) 183.4 (36.9, 203) ,0.001 FVB Mn1,
A230057G18Rik
rs13478488 60.3 5.65 0.07 3.8 202.8 (27.3, 229) 195.5 (32.1, 409) 185.4 (36.8, 198) ,0.001 FVB EG665194,
LOC100039529
SD: standard deviation; cM: centi-morgan; LOD: logarithm (base 10) of odds; LOD(SIM): the LOD scores derived from simple interval mapping; LOD(CIM): LOD scores
derived from composite interval mapping;
aThe proportion of contribution the genetic polymorphism on the overall variation of the immobility time in FST after fluoxetine treatment.
bP-value for one way analysis of variance.
cThe allele that shows significantly shorter immobility time in FST after fluoxetine treatment than the other allele.
dThe list of the gene located in 1 mega-bases from the SNP.
doi:10.1371/journal.pone.0032984.t001
Figure 3. LOD scores for linkage for FSTFLX. The solid red line at LOD =3.33 and the blue dashed line at LOD =4.68 denote the genome-wide
significance threshold for FSTFLX (SIM) and FSTFLX (CIM), respectively. The gray zone indicates the 2-LOD confidence interval. FST: forced swim test;
FSTFLX: immobility in the mouse FST with fluoxetine treatment; LOD: logarithm of odds; SIM: simple interval mapping; CIM: composite interval
mapping.
doi:10.1371/journal.pone.0032984.g003
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B6 and FVB mice. In addition, two genetic variants in Zfp326, one
with amino acid change (rs33550587, Asp494Gly) and one in the
39-UTR region (rs13473815), are associated with the mouse FST
response to fluoxetine (Figure 4). These findings provide further
evidence supporting the involvement of Zfp326 in the mouse FST
response to fluoxetine and explaining the discrepancy in sensitivity
to fluoxetine between B6 and FVB mice.
Association between ZNF326 Variations and Human
Responses to Antidepressants
Since the FST is a widely used animal model in predicting
antidepressant efficacy, it is imperative to examine the role of
human homologue of mouse Zfp326, ZNF326, in predicting the
efficacy of fluoxetine in humans. We found that rs2816881-A and
rs10922744-G and the A–G haplotype were significantly associ-
ated with a favorable response in patients with MDD after 8 weeks
of antidepressant treatment (Table 2). The effect of the two SNPs
Figure 4. The association of mouse Zfp326 function SNP with FST response to fluoxetine treatment. Genetic variations in Zfp326,
rs33550587 (Asp494Gly) (4a) and rs13473815 (4b), are associated with the mouse response to fluoxetine in the FST. The B66FVB-F2 mice were
grouped according to genotype. * p,0.05;
#p,0.0001. The digits in the bars represent the number of animals in each group. Zfp326: zinc finger
protein 326 gene; SNP: single nucleotide polymorphism; FST: forced swim test.
doi:10.1371/journal.pone.0032984.g004
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rs2816881 and rs10922744 are coding synonymous SNPs and do
not change the corresponding amino acid in the ZNF326 protein
sequence. According to the finding of Nembaware et al.’s study,
rs2816881 and its surrounding nucleotide sequence constitute
a splicing regulatory sequence located at the exonic splicing
enhancer elements of ZNF326 [43]. Meanwhile, in silico prediction
shows that both SNPs may have an effect on the ZNF326 RNA
secondary structure (Figure S2). In addition, rs2816881 and
rs10922744 are in strong linkage disequilibrium with another
Figure 5. Zfp326 mRNA expressions in different brain regions in B6 and FVB mice. The level of Zfp326 mRNA was normalized by the level of
cyclophilin A in the same region in each mouse. ‘‘**’’ and ‘‘*’’ represent a p-value lower than 0.01 and 0.05, respectively, comparing FVB with B6 in the
same brain region with the Many-Whitney U test. ‘‘
#’’ indicates a p-value lower than 0.05, comparing the same brain region of mice treated with
saline or fluoxetine using the Many-Whitney U test. n=8,10 mice for each bar. FLX: fluoxetine. FC: frontal cortex; Hip: hippocampus; HTh:
hypothalamus; Amy: amygdala; NAc: nucleus accumbens; Th: thalamus; St: striatum.
doi:10.1371/journal.pone.0032984.g005
Table 2. Genotype and allele distribution of ZNF326 polymorphisms in the controls, and in the patients with major depressive





SNP Genotype/allele MDD (%) Control (%) Responder (%) Non-responder (%)
rs2816881 CC 488 (84.3) 437 (81.7) 145 (84.8) 87 (96.7)
(Val412Val) CA 84 (14.5) 94 (17.6) 23 (13.5) 3 (3.3)
AA 7 (1.2) 4 (0.7) 3 (1.8) 0 (0.0)
P-value(genotype) 0.305 0.007
#
C allele 1060 (91.5) 968 (90.5) 313 (91.5) 177 (98.3)
A allele 98 (8.5) 102 (9.5) 29 (8.5) 3 (1.7)
P-value(allele) 0.377 0.0017
#
rs10922744 AA 480 (83.9) 432 (81.5) 145 (84.3) 86 (96.6)
(Glu505Glu) AG 85 (14.9) 95 (17.9) 24 (14.0) 3 (3.4)




A allele 1045 (91.3) 959 (90.5) 314 (91.3) 175 (98.3)
G allele 99 (8.7) 101 (8.5) 30 (8.7) 3 (1.7)
P-value(allele) 0.475 0.001
#
*The P-value in boldface indicates the significance survived after correction for multiple comparisons (adjusted significant threshold with Bonferroni’s procedure:
P,0.0125). ‘‘#’’ denotes the p-value obtained from Fisher exact test.
doi:10.1371/journal.pone.0032984.t002
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mRNA expression in human liver (http://hapmap.ncbi.nlm.nih.
gov/index.html.en) [44]. Therefore, rs2816881 and rs10922744
may affect ZNF326 mRNA expressions through changing ZNF326
RNA secondary structure, or disrupting normal gene splicing and
causing aberrant splicing of either a proportion or all of the
transcripts produced [43]. Interestingly, a recent genome-wide
association study conducted in the GENDEP project reported that
three SNPs (rs2136093, rs6701608 and rs2136094), about
0.20 Mb away from ZNF326 in human chromosome 1 were in
suggestive association (p=3.82–5.56610
27) with antidepressant
responses [45]. Based on the convergent evidence obtained from
mouse FSTFLX-QTL mapping, human study in Uher et al. [45],
and our results, it is highly possible that zinc finger protein 326 is
involved in regulating the effect of fluoxetine in mice and humans.
The Function of Zfp326 Needs Further Exploration
The Zfp326 gene encodes a protein that contains two C2H2-
type zinc finger motifs and glutamic acid-rich domains in the C-
terminal region [46]. It exhibits DNA-binding activity in a zinc-
dependent manner and plays a role in regulating cell growth
[46]. Zfp326 is thought to play a role in neuronal differentiation
because its expression in the neuro-epithelium of the brain and
neural tube in E11.5 embryos increased and its mRNA and
protein were transiently elevated in cells treated with retinoic
acid [41]. Recently, another human zinc finger protein ZNF804A
gene, which also encodes a protein product with a C2H2-type
domain like Zfp326, was reported to be associated with
schizophrenia and a broader psychosis phenotype [47,48].
However, detailed information about the Zfp326 gene and its
mechanism of functioning is still unknown, and the role of the
gene in the pathogenesis of depression and antidepressant effect
requires further characterization.
Discrepancies Among Inbred Mouse Strains in Response
to Antidepressants
In the first part of the study, we identified B6 as the fluoxetine-
insensitive strain and FVB as the fluoxetine-sensitive strain. In
a study of such a huge scale, the use of an automatic recording
device is an important factor in achieving significant linkage
results. Crowley et al. suggested that the use of an automatic
recording device for scoring rodent behavior in the FST had
many advantages over manual scoring [49], which included
consistency and reliability across different experiments, raters and
laboratories [49]. However, the applicability of an automatic
device for the FST requires validation through contrasting with
manual scoring procedures [49]. Prior to the commencement of
the study, we proved that the correlation between manual and
device scoring for the FST was high (Pearson correlation
coefficient =0.93–0.96, p,0.001). In order to confirm the
sensitive and insensitive strains for the subsequent heritability test
and QTL analysis, replication experiments using a fixed dose of
20 mg/kg of fluoxetine and independent batches of B6, BALB
and FVB mice were conducted. The results confirmed that the
FVB and B6 were respectively sensitive and insensitive to 20 mg/
kg of fluoxetine treatment in the FST (result 3.3). Possible
psychostimulant or hyperactivity-inducing effects of fluoxetine
[38] on the FST were ruled out, because neither the B6 nor FVB
mice displayed increased activity in the open field test 30 minutes
after fluoxetine treatment (Table S2).
Conclusion
Through genotyping of 199 SNPs of 865 male B66FVB F2
mice and applying SIM and CIM analysis, we localized the trait to
the 47.3–54.2 cM region of mouse chromosome 5. Inside the
region, a rarely studied gene, Zfp326, deserves special attention,
because (1) its expression can be regulated by fluoxetine in the
thalamus of FVB, (2) its expression differs between B6 and FVB
mice in some brain areas and the discrepancies can be altered by
fluoxetine, and (3) the SNPs in Zfp326 were found to be associated
with sensitivity to fluoxetine in the F2 mice. Most importantly,
polymorphisms of the human homologue of Zfp326, ZNF326, were
found to be associated with therapeutic response to SSRI
treatment in patients with major depressive disorder. By studying
the function of Zfp326 or ZNF326, we may unravel the mechanism
of antidepressant action and gain further insight into the pathology
of major depressive disorder.
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